This information may be even more relevant now that other therapies, namely SGLT‐2 inhibitors, are being introduced for the management and prevention of diabetic kidney disease (Ingelfinger and Rosen, 2019). The gene discussed is SLC5A2; the disease is diabetic kidney disease.